演題詳細

一般口演 / Oral Session

一般口演 2 (Oral Session 2) :鉄キレート療法

print

日程
2013年10月11日(金)
時間
10:30 - 11:30
会場
第3会場 / Room No.3 (さっぽろ芸文館 3F 蓬莱)
座長・司会
金森 平和 (Heiwa Kanamori):1
1:神奈川県立がんセンター 血液内科
 
前へ戻る

Analysis of hematologic improvement with iron chelation therapy using deferasirox in aplastic anemia

演題番号 : OS-1-9

定免 渉 (Wataru Jomen):1、黒田 裕行 (Hiroyuki Kuroda):1、吉田 正宏 (Masahiro Yoshida):1、山田 充子 (Michiko Yamada):1、安部 智之 (Tomoyuki Abe):1、櫻井 環 (Tamaki Sakurai):1、藤井 重之 (Shigeyuki Fujii):1、前田 征洋 (Masahiro Maeda):1、藤田 美悧 (Miri Fujita):2、長嶋 和郎 (Kazuo Nagashima):2、佐藤 昌則 (Masanori Sato):3、松野 鉄平 (Teppei Matsuno):3、宮西 浩嗣 (Koji Miyanishi):3、小船 雅義 (Masayoshi Kobune):3、加藤 淳二 (Junji Kato):3

1:Gastroenterology Hematology/Oncology, Int.Med, Steel Memorial General Hospital, Japan、2:Dept. of Pathology, Steel Memorial General Hospital, Japan、3:Fourth Dept. of Internal Medicine, Sapporo Medical University

 

Recently, there are several reports of hematologic responses to deferasirox (DFX) therapy in transfusional iron overload patients affected by aplastic anemia (AA). We retrospectively analyzed hematologic improvement of DFX in AA patients at our hospital. Nine patients with transfusional iron overload who received iron chelation therapy (ICT) with DFX in our hospital from April 2010 to March 2013 were studied. Of these, one patient had non-severe stage 2, while 8 patients had severe stage 3 to 5. Initial median dose of DFX was 12.0 mg/kg per day, median duration of treatment was 13.4 months, while 2 patients discontinued the treatment. Hematologic improvements were observed in 44.4% (4/9) of the patients, all of which achieved blood transfusion independence, while 3 of patients achieved platelet transfusion independence. Median time to transfusion independence was 4.3 months and 7.2 months respectively. In these 4 patients, median serum ferritin level was 1708 ng/ml immediately before ICT, but levels decreased to less than 500 ng/ml after ICT. ICT with DFX can result in hematologic improvement in those patients with transfusion-dependent AA. Relationship of refractory to immunosuppressive therapy (IST) and excessive iron accumulation of the bone marrow may be important in dyshematopoiesis of transfusion-dependent AA patients. Consequently, in such patients, induction of DFX should be considered as a potential treatment.

前へ戻る